R
1.43
0.20 (16.54%)
| 前收盘价格 | 1.23 |
| 收盘价格 | 1.23 |
| 成交量 | 124,571 |
| 平均成交量 (3个月) | 499,237 |
| 市值 | 3,290,370 |
| 预期市盈率 (P/E Forward) | 1.43 |
| 价格/销量 (P/S) | 0.190 |
| 股市价格/股市净资产 (P/B) | 203.21 |
| 52周波幅 | |
| 利润日期 | 10 Apr 2025 |
| 营业毛利率 | -102.80% |
| 营业利益率 (TTM) | -69.57% |
| 季度收入增长率 (YOY) | 382.00% |
| 总债务/股东权益 (D/E MRQ) | 914.75% |
| 流动比率 (MRQ) | 0.540 |
| 营业现金流 (OCF TTM) | -9.37 M |
| 杠杆自由现金流 (LFCF TTM) | -5.39 M |
| 资产报酬率 (ROA TTM) | -37.28% |
| 股东权益报酬率 (ROE TTM) | -1,708.61% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 看涨 | 混合的 |
| Drug Manufacturers - Specialty & Generic (全球的) | 看涨 | 混合的 | |
| 股票 | Redhill Biopharma Ltd. | - | - |
AIStockmoo 评分
1.1
| 分析师共识 | 2.0 |
| 内部交易活动 | NA |
| 价格波动 | 0.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 1.13 |
|
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Growth |
| 机构持股比例 | 4.30% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Gamma Investing Llc | 30 Jun 2025 | 2,061 |
| Financial Management Professionals, Inc. | 30 Jun 2025 | 9 |
| Vermillion Wealth Management, Inc. | 30 Jun 2025 | 2 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合